Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 318 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
REVIEW ARTICLE
Year : 2015  |  Volume : 19  |  Issue : 2  |  Page : 228-235

Challenges and controversies in diagnosis and management of gonadotropin dependent precocious puberty: An Indian perspective


1 Department of Endocrinology and Metabolism, Institute of Post graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, West Bengal, India
2 Department of Endocrinology, Post-graduate Institute of Medical Education and Research and Dr. Ram Manohar Lohia Hospital, New Delhi, India

Date of Web Publication14-Jan-2015

Correspondence Address:
Deep Dutta
Department of Endocrinology, Endocrine Clinic, Nursing Home Annex, Post graduate Institute of Medical Education and Research and Dr. Ram Manohar Lohia Hospital, New Delhi - 110 001
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.149316

Rights and Permissions
   Abstract 

Managing precocious puberty (PP) has been a challenge due to lack of standardized definition, gonadotrophins assay, gonadotrophin stimulation, timings for blood sampling, and parameters for assessing outcomes. This review evaluated available literature to simplify the algorithm for managing gonadotrophin dependent/central PP (CPP), with an Indian perspective. CPP is one of the commonest forms of PP and mimics the normal course of puberty, at an age <8 and 9 years for girls and boys respectively. Basal and post gonadotrophin hormone releasing hormone analog (GnRHa) luteinizing hormone (LH) ≥0.3-0.6 IU/L and ≥4-5 IU/L (30-60 min after GnRH/GnRHa administration) respectively, using modern ultrasensitive automated chemiluminescence assays, can be considered positive for central puberty initiation. Uterine length of >3.5 cm and uterine volume of >1.8 ml are two most specific indicators for true CPP. Therapy is indicated in children with CPP with accelerated bone age, height advancement, or psychosocial stress. Treatment goal is to halt puberty progression to a socially acceptable age, allowing the child to attain optimal height potential. GnRHa is the treatment of choice, with best height outcomes when initiated <6 years age. Treatment is recommended till 11 years age. LH suppression to <3 U/L may be a reasonable target in patients on GnRHa therapy. Medroxyprogesterone acetate holds an important place in managing PP in India, cause of high costs associated with GnRHa therapy. There is an urgent need for clinical trials from India, for establishing Indian cut-off for diagnosis, treatment and follow-up of children with PP.

Keywords: Adrenarche, gonadotropin releasing hormone analog, gonadotropins, medroxyprogesterone acetate, menarche, precocious puberty, pubarche, thelarche


How to cite this article:
Kumar M, Mukhopadhyay S, Dutta D. Challenges and controversies in diagnosis and management of gonadotropin dependent precocious puberty: An Indian perspective. Indian J Endocr Metab 2015;19:228-35

How to cite this URL:
Kumar M, Mukhopadhyay S, Dutta D. Challenges and controversies in diagnosis and management of gonadotropin dependent precocious puberty: An Indian perspective. Indian J Endocr Metab [serial online] 2015 [cited 2018 Nov 15];19:228-35. Available from: http://www.ijem.in/text.asp?2015/19/2/228/149316


   Introduction Top


Onset of development of secondary sexual characteristics (as the first step toward attaining reproductive capacity) before the age of 8 and 9 years in girls and boys respectively has traditionally been used for defining precocious puberty (PP). [1] PP is a spectrum disorder, which may manifest with either development of all the secondary sexual features (progressive PP) or may occasionally present as isolated premature thelarche, adrenarche or menarche.

Optimal management of PP is an important cause of its considerable long-term biological, psychosocial and health implications. Early onset of puberty and untreated PP has been linked to compromised adult height, increased occurrence of metabolic syndrome, dyslipidemia, dysglycemia, cardiovascular events, hyperandrogenism, increased risk of breast cancer, increased psychological disturbance, risk taking behavior and sexual activity. [2] However, the diagnosis and management of PP is complicated by lack of standardized age cut-offs for clinical diagnosis, the varied clinical presentation, lack of internationally standardized gonadotrophins (especially luteinizing hormone [LH]) assay, lack of standardized agents for gonadotrophin stimulation, timings for sampling for post-stimulatory LH, a large plethora of available pharmacologic agents, lack of standardized biochemical parameters for monitoring response to therapy and assessing long-term outcomes.

This article aims to review the available literature to simplify the algorithm for diagnosis and management of PP (especially gonadotrophin dependent PP), keeping in mind the resources available in India currently.


   Methods Top


Search strategy and selection criteria

References for this review were identified through searches of PubMed, Medline and Embase for articles published till October 2014, by use of the terms "PP" [MeSH Terms] OR "pubertal onset" [All Fields] OR "puberty" [All Fields]. The reference lists of the articles thus identified were also searched. The search was not restricted to English language literature.


   Results Top


The prevalence of PP among Indian children is not known. The prevalence of PP is about 10 times higher in girls than boys with estimated register-based population prevalence of approximately 0.2% in girls and below 0.05% in boys (Denmark). [3] Secular trends from industrialized European countries and USA over the past 150 years have suggested a constant decline in the age of menarche, at a rate of about 2-3 months per decade. [4] Accordingly, in some developed countries, the ages of 7 years for white girls and 6 years for black girls have been proposed to define onset of PP from the more universally accepted cut offs of 8 and 9 years for girls and boys respectively. This decline in age of onset of puberty has also been associated with increased occurrence of children presenting with PP across the globe. [5],[6] Improvement in nutritional status, better control of infections, better quality of life, increased childhood obesity, low birth weight followed by rapid gain of weight, genetic, ethnic factors, international adoption, increased exposure to endocrine disrupting chemicals are believed to have some role. [5],[6]

The earliest clinical sign suggestive of onset of puberty is breast enlargement (thelarche) in girls and increase in testicular volume in boys, with the entire process of maturation completing within 4 years of onset. [1],[7],[8] Kisspeptin produced by arcuate nucleus and anteroventral periventricular area of the hypothalamus is critical to puberty initiation. Neurokinin B and dynorphin from the same neurons stimulate and inhibit the release of kisspeptin respectively, and hence these kisspeptin, neurokinin and dynorphin neurons have now been recognized to be central to puberty initiation. [9],[10]

Etiology

Etiology of gonadotrophin releasing hormone (GnRH) dependent PP (central PP [CPP]), one of the most common forms of PP, remains undetermined in a majority of children (girls > boys), with idiopathic CPP comprising 90% of cases in girls, as per western literature. [7] However, idiopathic CPP is believed to be less common in India, both in girls as well as boys. Central nervous system (CNS) infections are an important secondary cause of CPP in India. In a series of 140 patients with PP from Mumbai, a definitive cause for CPP could be established in 56% (10 out of 18) boys and 21% (16 out of 77) girls, with hypothalamic hamartoma followed by neurotuberculosis being the two most common causes. [11] Some of the common causes of PP have been elaborated in [Table 1].
Table 1: Common causes of precocious puberty

Click here to view


Clinical diagnosis

Evaluation of PP should include complete family history (age at onset of puberty in parents and siblings) patient's details of age at onset of puberty and progression of pubertal manifestations. Any evidence suggesting possible CNS dysfunction, like recurrent vomiting, headache, increased head circumference, visual impairment, or seizures should be noted. Growth pattern and velocity should be meticulously recorded. Sexual maturity is assessed using Tanner's staging. CPP in contrast to peripheral PP (PPP) classically mimics the normal course of pubertal development of thelarche, followed by adrenarche and menarche, and is associated with height acceleration and advancement of bone age (BA). Documentation of height velocity and BA is important cause certain incomplete variants of PP may be associated with normal height velocity and BA (isolated premature thelarche, premature adrenarche), and these children do not warrant therapy with GnRH analogs (GnRHa). Development of acne, oily skin, and apocrine body odor support the development of adrenarche.

Examination of testicular volume is important in males, as boys with CPP typically have symmetric enlargement of bilateral testis in pubertal range (>4 ml, or >2.5 cm in length), in contrast to PPP, which typically have disproportionately small testis, as compared to the degree of virilization. [12] Exceptions to this include PPP due to human chorionic gonadotropin secreting tumors and familial male limited PP (testotoxicosis, due to mutation in LH receptor).

Perhaps the most common cause of PPP is congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Diagnosis is easy and early in females, even in the absence of salt wasting crisis, due to the varied degree of virilization of external genitalia at birth. Males with 21-hydroxylase deficiency, in the absence of salt wasting, often present at a later age with PP. Testicular volume though typically small (prepubertal) in these children, a small proportion will develop secondary CPP (due to long-term exposure to sex steroids, through mechanisms not well understood), resulting in increase in testicular volume. This has also been observed in other causes of PPP, and typically occurs once the chronic exposure to sex steroids is eliminated, like after initiation of treatment for CAH. In addition, development and enlargement of the adrenal rests may also be responsible for increased testicular volume in CAH. These adrenal rests can be made out separately from testis, on careful testicular palpation.

Investigations

The main aim of biochemical evaluation is to confirm the diagnosis of CPP (GnRH dependent), distinguish incomplete nonprogressive forms of PP like premature thelarche, premature adrenarche from true PP. This involves estimation of LH in the basal state, as well as post GnRH/GnRHa stimulation. Various studies have reported different cut-offs of basal LH for the diagnosis of hypothalamic pituitary gonadal (HPG) axis activation (puberty initiation), a result of usage of different assay systems for LH estimation, having different sensitivity and assay coefficient of variation [Table 2] and [Table 3]. In general a basal LH ≥ 0.3-0.6 IU/L using modern ultrasensitive automated chemiluminescence assays (now available in India in most tertiary care centers), can be considered to be positive for HPG axis activation. [7],[8] GnRH is not available in India. Triptorelin (100 mcg) followed by leuprolide (20 mcg/m 2 ) are the 2 most commonly available GnRHa for GnRHa stimulation test in India. These preparations are usually administered subcutaneous or intramuscular. There is no available standard for timing of blood sampling for LH estimation post GnRHa administration. Generally an early sampling 30-60 min after GnRH/GnRHa administration is considered to be highly sensitive and specific for diagnosis, and a late sampling between 2 and 4 h may also be done, especially when a GnRHa are used for stimulation. [13],[14],[15] Different studies have again reported different levels of post-GnRHa stimulated LH for the diagnosis of HPG axis activation [Table 2] and [Table 3]. In general a stimulated LH ≥ 4-5 IU/L using modern ultrasensitive automated chemiluminescence assays can be considered to be positive for HPG axis activation. [7],[8] Follicle stimulating hormone (FSH) estimation is in general not helpful cause of the considerable overlap of prepubertal values with puberty, and cause of its elevation in premature thelarche. However, a peak LH/peak FSH > 1 (>0.6 in some studies) is also helpful in differentiating true CPP from premature thelarche, which has a predominant FSH response. [4],[8]
Table 2: Studies showing basal and poststimulated LH levels diagnostic of hypothalamic pituitary gonadal axis
activation and puberty initiation in girls


Click here to view
Table 3: Studies showing basal and poststimulated LH levels diagnostic of hypothalamic pituitary gonadal axis
activation and puberty initiation in boys


Click here to view


Ultrasonography of uterus and ovaries by an experienced radiologist is a very useful investigation in affected females. An uterine length of >3.5 cm, followed by uterine volume of >1.8 ml are believed to be the 2 most specific indicators for true CPP, and are useful in differentiating CPP from premature thelarche or adrenarche. [12],[20] Ovarian cysts can be found in both CPP and PPP, but cysts >9 mm are also highly suggestive of CPP. [21]

As per standard textbooks, all boys with CPP and girls only with suggestive symptoms should undergo MRI brain for evaluation of secondary sinister causes of CPP. [4],[8] However, it may be a good practice to do MRI brain in all children of CPP < 6 years age, irrespective of sex. MRI may be avoided (not cost effective) in children >6 years age, especially girls who do not have symptoms suggestive of secondary underlying pathology.

Ancillary investigations are always recommended as per the clinical presentation of the patient, to establish the etiology of CPP or PPP [Table 1]. It has been suggested that the children with mild pubertal development with ambiguous biochemical report may be monitored closely for 3-6 months for growth and BA acceleration before treatment initiation, at the cost of perhaps compromising on the final height outcome. [22] Therapy is indicated in children with definitive diagnosis of CPP, rapid advancement of height and BA (>2.5 standard deviation for chronologic age), serum testosterone >75 ng/dl (in males <8 years age), estradiol (>10 pg/ml in females), or in the setting of parental anxiety, psychosocial stress. [12] Serum estradiol however has a high overlapping range in normal and PP limiting its use. In addition, estradiol assays are notorious for having poor reliability and reproducibility.

Treatment

The main goals of treatment of PP are to halt/delay the process of puberty progression, till an age commensurate with peers of the child, to allow for normal social, psychological and intellectual development of the child, relieve the parents of the associated anxiety, and importantly allow the child to attain the optimal height potential, as untreated PP is associated with accelerated and advanced epiphyseal fusion, resulting in height loss.

Gonadotrophin releasing hormone analog is the mainstay of treatment as they help in achieving all the treatment goals when used in the appropriate clinical setting. Adult height preservation with GnRHa is best when initiated in children diagnosed before 6 years age, variable when initiated between 6 and 8 years age, and probably has little benefit when initiated after 8 years age. [7] Good predictors of height outcomes, include younger chronological age (CA), younger BA, greater height standard deviation score for CA at initiation of therapy and a higher predicted adult height using Bayley-Pinneau tables. [23],[24] GnRHa should generally be continued till 11 years age, when pubertal progression is more likely to commensurate with peers at school and neighborhood. Continuing use of GnRHa beyond CA of 11 years and/or BA of 12-12.5 years has been shown to have conflicting effect on final height outcomes in different studies. [22],[24],[25]

Gonadotrophin releasing hormone analog discontinuation is associated with initiation of menses within 1-2 years. [26],[27] The authors frequently observed the occurrence of polycystic ovarian syndrome (PCOS) in a large majority of children following cessation of GnRHa therapy. GnRHa however is believed to have no impact on long-term menstrual regularity, reproductive potential, number of pregnancies and pregnancy outcomes. [28],[29] Bone mineral density generally dips with the start of GnRHa but normalizes after discontinuation of therapy, with no impact on long-term outcomes. [2]

Concern for long-term metabolic outcomes (metabolic syndrome) and PCOS remains a concern in patients with PP, with currently available literature showing conflicting outcomes. [28],[30] Interpreting these studies has been a challenge in view of use of different diagnostic criteria, race/ethnicity and several biases. [2],[28],[29],[30] GnRHa therapy does not modulate the hyperandrogenism in later life associated with PP. [2] Limited data (only two studies) is suggestive of no impact of GnRHa therapy on psychologic outcomes of girls with CPP. [31],[32]

Height outcomes with different GnRHa therapy across the globe have been elaborated in [Table 4]. The different GnRHa and their dosages currently available in India for treatment of PP have been elaborated in [Table 5]. Leurpolide depot is perhaps most commonly used followed by triptorelin depot preparation. No preparation of GnRHa has any added advantage over another. Buserelin and histrelin, available in Europe and USA, are not currently available in India. Monthly depot injections of leuprolide and triptorelin are most commonly used. Recently, 3 monthly depot preparations are also available in the market, with the advantage of reduced annual cost of therapy. However, concerns have been raised about the duration of efficacy of the 3 monthly preparations, with fears of wearing off of efficacy in the last of the 3 months (unpublished data). The first injection of GnRHa is associated with a transient surge in LH and FSH resulting in a transient increase in estradiol levels, which then rapidly reduces following down regulation of GnRH receptor, usually within a fortnight. [12] This transient surge in estradiol may result in vaginal spotting/bleeding in a small fraction of female patients following the first injection. Hence, it may be important to counsel the parents regarding the same beforehand to allay any anxiety. Co-injection of depot medroxy-progesterone acetate (MPA) only with the first dose of GnRHa may be a reasonable option to prevent this estradiol surge and the associated vaginal bleed. Vaginal bleed if noticed following subsequent injections are more likely due to lack of adequate gonadotropin suppressing warranting more frequent LH levels monitoring, increase in dose/frequency of GnRHa injections. However, there are no guidelines or recommendations for timing of estimation of serum LH (basal/post stimulated, agent for stimulation), as well as level of serum LH during follow up of GnRHa therapy for therapy modulation. The only study done in India in patients on 11.25 mg leuprolide depot intramuscular injections has suggested 3 h LH post injection of depot leuprolide, to be useful for monitoring therapy in patients with CPP cause of its convenience and cost effectiveness. [33] Ideally, serum LH should be suppressed to undetectable levels in patients on GnRHa therapy, which may however be not practically feasible in the majority of the patients. A suppression of LH to <3 U/L may be a reasonable target in patients on GnRHa therapy, [34] with few studies reporting LH <4 U/L also as an acceptable LH suppression cut-off. [35],[36],[37] Studies are warranted to evaluate the LH levels not only after administration of GnRHa depot injection, but also perhaps a few days before the next scheduled dose of GnRHa. A persistently suppressed serum LH on both occasions may be an important predictor of response to therapy.
Table 4: Height outcomes of different gonadotrophin hormone releasing hormone analogs in managing central
precocious puberty


Click here to view
Table 5: Gonadotrophin hormone releasing hormone
analog depot preparations available in India


Click here to view


However, use of GnRHa in managing CPP in India may be limited cause of the associated costs, making it unaffordable to a large fraction of the population. MPA or cyproterone acetate (CPA) should be used for managing PP in children who cannot afford GnRHa. MPA may be a reasonably good option for managing CPP in children >6 years of age, where use of GnRHa has been associated with minimal gains in height outcomes. MPA/CPA are useful in halting puberty progression, but have no beneficial impact on final height outcomes. [12] Advantages of MPA include its low cost, ease of administration, and established efficacy in halting puberty progression.

MPA has multiple mechanisms of actions. It inhibits central gonadotropin release by acting on hypothalamic pulse generator, and it also directly inhibits gonadal steroidigenesis by inhibiting 3-beta hydroxysteroid dehydrogenase 2 enzyme. [37] Its glucocorticoid mimetic action is responsible for adrenocorticotrophic hormone (ACTH) suppression, hypertension and development of cushingoid habitus. MPA use is associated with bone mineral loss, especially if used for a long period. [8],[37] CPA has advantages and disadvantages similar to MPA, except for its ACTH and cortisol suppressing effect leading to symptoms of iatrogenic adrenal insufficiency in a subset of patients. MPA is usually initiated in the form of depot deep intramuscular injections, at a low dose of 50 mg per month, which can be increased up to 400 mg per month, or the dosing frequency can be reduced to fortnightly. [8],[37]

Future directions

There is an urgent need for clinical trials from India, for the establishment of Indian cut-offs for diagnosis, treatment and follow up of children with PP. Trials should focus on evaluating the reliability of measurement of uterine length and volume, and ovarian volume (cheap and easy to do measure) in predicting puberty onset, and their relationship with more costly and less reproducible biochemical tests like basal and stimulated LH.


   Conclusion Top


Precocious puberty is a common problem seen in endocrinology practice. Diagnosis and management of PP remains a challenge in the absence of standardized guidelines. GnRHa is the agents of choice for managing CPP. MPA still holds an important place in the management of PP in India, especially in children >6 years age[49].

 
   References Top

1.
Mul D, Fredriks AM, van Buuren S, Oostdijk W, Verloove-Vanhorick SP, Wit JM. Pubertal development in The Netherlands 1965-1997. Pediatr Res 2001;50:479-86.  Back to cited text no. 1
    
2.
Willemsen RH, Elleri D, Williams RM, Ong KK, Dunger DB. Pros and cons of GnRHa treatment for early puberty in girls. Nat Rev Endocrinol 2014;10:352-63.  Back to cited text no. 2
    
3.
Teilmann G, Pedersen CB, Jensen TK, Skakkebaek NE, Juul A. Prevalence and incidence of precocious pubertal development in Denmark: An epidemiologic study based on national registries. Pediatrics 2005;116:1323-8.  Back to cited text no. 3
    
4.
Styne DM, Grumbach MM. Puberty: Ontogeny, neuroendocrinology, physiology, and disorders. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, editors. William's Textbook of Endocrinology. 12 th ed., Vol. 25. Elsevier Saunders. p. 1055-6.  Back to cited text no. 4
    
5.
Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: Implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999;104:936-41.  Back to cited text no. 5
    
6.
Deng F, Tao FB, Liu DY, Xu YY, Hao JH, Sun Y, et al. Effects of growth environments and two environmental endocrine disruptors on children with idiopathic precocious puberty. Eur J Endocrinol 2012;166:803-9.  Back to cited text no. 6
    
7.
Fuqua JS. Treatment and outcomes of precocious puberty: An update. J Clin Endocrinol Metab 2013;98:2198-207.  Back to cited text no. 7
    
8.
Rosenfield RL, Cooke DW, Radovick S. Puberty and its Disorders in the Female. In: Sperling MA, editor. Pediatric Endocrinology. 4 th ed., Vol. 15. Saunders Elsevier; 2014. p. 612-5.  Back to cited text no. 8
    
9.
Wakabayashi Y, Nakada T, Murata K, Ohkura S, Mogi K, Navarro VM, et al. Neurokinin B and dynorphin A in kisspeptin neurons of the arcuate nucleus participate in generation of periodic oscillation of neural activity driving pulsatile gonadotropin-releasing hormone secretion in the goat. J Neurosci 2010;30:3124-32.  Back to cited text no. 9
    
10.
Mayer C, Acosta-Martinez M, Dubois SL, Wolfe A, Radovick S, Boehm U, et al. Timing and completion of puberty in female mice depend on estrogen receptor alpha-signaling in kisspeptin neurons. Proc Natl Acad Sci U S A 2010;107:22693-8.  Back to cited text no. 10
    
11.
Bajpai A, Sharma J, Kabra M, Kumar Gupta A, Menon PS. Precocious puberty: Clinical and endocrine profile and factors indicating neurogenic precocity in Indian children. J Pediatr Endocrinol Metab 2002;15:1173-81.  Back to cited text no. 11
    
12.
Styne DM, Grumbach MM. Puberty: Ontogeny, neuroendocrinology, physiology, and disorders. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, editors. Williams Textbook of Endocrinology. 12 th ed., Vol. 25. Saunders Elsevier; 2012. p. 1144-71.  Back to cited text no. 12
    
13.
Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr 1995;127:47-52.  Back to cited text no. 13
    
14.
Lawson ML, Cohen N. A single sample subcutaneous luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppression in children with central precocious puberty receiving LHRH agonists. J Clin Endocrinol Metab 1999;84:4536-40.  Back to cited text no. 14
    
15.
Brito VN, Batista MC, Borges MF, Latronico AC, Kohek MB, Thirone AC, et al. Diagnostic value of fluorometric assays in the evaluation of precocious puberty. J Clin Endocrinol Metab 1999;84:3539-44.  Back to cited text no. 15
    
16.
Houk CP, Kunselman AR, Lee PA. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. Pediatrics 2009;123:e1059-63.  Back to cited text no. 16
    
17.
Sathasivam A, Garibaldi L, Shapiro S, Godbold J, Rapaport R. Leuprolide stimulation testing for the evaluation of early female sexual maturation. Clin Endocrinol (Oxf) 2010;73:375-81.  Back to cited text no. 17
    
18.
Resende EA, Lara BH, Reis JD, Ferreira BP, Pereira GA, Borges MF. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab 2007;92:1424-9.  Back to cited text no. 18
    
19.
Bizzarri C, Spadoni GL, Bottaro G, Montanari G, Giannone G, Cappa M, et al. The response to gonadotropin releasing hormone (GnRH) stimulation test does not predict the progression to true precocious puberty in girls with onset of premature thelarche in the first three years of life. J Clin Endocrinol Metab 2014;99:433-9.  Back to cited text no. 19
    
20.
Calcaterra V, Sampaolo P, Klersy C, Larizza D, Alfei A, Brizzi V, et al. Utility of breast ultrasonography in the diagnostic work-up of precocious puberty and proposal of a prognostic index for identifying girls with rapidly progressive central precocious puberty. Ultrasound Obstet Gynecol 2009;33:85-91.  Back to cited text no. 20
    
21.
Brauner R, Malandry F, Rappaport R. Predictive factors for the effect of gonadotrophin releasing hormone analogue therapy on the height of girls with idiopathic central precocious puberty. Eur J Pediatr 1992;151:728-30.  Back to cited text no. 21
    
22.
Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, ESPE-LWPES GnRH Analogs Consensus Conference Group, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752-62.  Back to cited text no. 22
    
23.
Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: Revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423-41.  Back to cited text no. 23
    
24.
Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999;141:140-4.  Back to cited text no. 24
    
25.
Oostdijk W, Rikken B, Schreuder S, Otten B, Odink R, Rouwé C, et al. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child 1996;75:292-7.  Back to cited text no. 25
    
26.
Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Iughetti L, Pasquino AM, et al. Menstrual cycle pattern during the first gynaecological years in girls with precocious puberty following gonadotropin-releasing hormone analogue treatment. Eur J Pediatr 2007;166:73-4.  Back to cited text no. 26
    
27.
Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB Jr. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: Long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999;84:44-9.  Back to cited text no. 27
    
28.
Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: Asingle center, long-term follow-up study. J Clin Endocrinol Metab 2010;95:109-17.  Back to cited text no. 28
    
29.
Neely EK, Lee PA, Bloch CA, Larsen L, Yang D, Mattia-Goldberg C, et al. Leuprolide acetate 1-month depot for central precocious puberty: Hormonal suppression and recovery. Int J Pediatr Endocrinol 2010;2010:398639.  Back to cited text no. 29
    
30.
Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:787-96.  Back to cited text no. 30
    
31.
Mul D, Versluis-den Bieman HJ, Slijper FM, Oostdijk W, Waelkens JJ, Drop SL. Psychological assessments before and after treatment of early puberty in adopted children. Acta Paediatr 2001;90:965-71.  Back to cited text no. 31
    
32.
Xhrouet-Heinrichs D, Lagrou K, Heinrichs C, Craen M, Dooms L, Malvaux P, et al. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy. Acta Paediatr 1997;86:808-15.  Back to cited text no. 32
    
33.
Acharya SV, Gopal RA, George J, Bandgar TR, Menon PS, Shah NS. Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty. Pituitary 2009;12:335-8.  Back to cited text no. 33
    
34.
Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002;87:4111-6.  Back to cited text no. 34
    
35.
Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr 2011;159:982-7.e1.  Back to cited text no. 35
    
36.
Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab 2012;97:1572-80.  Back to cited text no. 36
    
37.
Mericq V, Lammoglia JJ, Unanue N, Villaroel C, Hernández MI, Avila A, et al. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: Preliminary results. Clin Endocrinol (Oxf) 2009;71:686-90.  Back to cited text no. 37
    
38.
Bouvattier C, Coste J, Rodrigue D, Teinturier C, Carel JC, Chaussain JL, et al. Lack of effect of GnRH agonists on final height in girls with advanced puberty: A randomized long-term pilot study. J Clin Endocrinol Metab 1999;84:3575-8.  Back to cited text no. 38
    
39.
Galluzzi F, Salti R, Bindi G, Pasquini E, La Cauza C. Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy. Acta Paediatr 1998;87:521-7.  Back to cited text no. 39
    
40.
Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr 1998;157:363-7.  Back to cited text no. 40
    
41.
Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84:4583-90.  Back to cited text no. 41
    
42.
Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999;81:329-32.  Back to cited text no. 42
    
43.
Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: Importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab 1999;84:1973-8.  Back to cited text no. 43
    
44.
Leger J, Reynaud R, Czernichow P. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment? J Pediatr 2000;137:819-25.  Back to cited text no. 44
    
45.
Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: The National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711-6.  Back to cited text no. 45
    
46.
Kempers MJ, Otten BJ. Idiopathic precocious puberty versus puberty in adopted children; auxological response to gonadotrophin-releasing hormone agonist treatment and final height. Eur J Endocrinol 2002;147:609-16.  Back to cited text no. 46
    
47.
Adan L, Chemaitilly W, Trivin C, Brauner R. Factors predicting adult height in girls with idiopathic central precocious puberty: Implications for treatment. Clin Endocrinol (Oxf) 2002;56:297-302.  Back to cited text no. 47
    
48.
Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: Impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008;93:190-5.  Back to cited text no. 48
    
49.
Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007;92:3483-9.  Back to cited text no. 49
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]


This article has been cited by
1 Neonatal endocrine labomas - pitfalls and challenges in reporting neonatal hormonal reports
Sachin Chittawar,Deep Dutta,Deepak Khandelwal,Rajiv Singla
Indian Pediatrics. 2017; 54(9): 757
[Pubmed] | [DOI]
2 Primary Mediastinal Pure Seminomatous Germ Cell Tumor (Germinoma) as a Rare Cause of Precocious Puberty in a 9-Year-Old Patient
Alejandra Bravo-Balado,Lynda Torres Castellanos,Adriana Carrillo Rodríguez,Daniel Gómez Zapata,Juan Javier Lammoglia Hoyos,Rafael Andrade,Jaime Pérez Niño
Urology. 2017;
[Pubmed] | [DOI]
3 Disorders of puberty
Charles Sultan,Laura Gaspari,Laurent Maimoun,Nicolas Kalfa,Françoise Paris
Best Practice & Research Clinical Obstetrics & Gynaecology. 2017;
[Pubmed] | [DOI]
4 Precocious puberty
Taymour Mostafa
Human Andrology. 2016; 6(2): 31
[Pubmed] | [DOI]
5 Central precocious puberty: revisiting the diagnosis and therapeutic management
Vinícius Nahime Brito,Angela Maria Spinola-Castro,Cristiane Kochi,Cristiane Kopacek,Paulo César Alves da Silva,Gil Guerra-Júnior
Archives of Endocrinology and Metabolism. 2016; 60(2): 163
[Pubmed] | [DOI]
6 Causes, diagnosis, and treatment of central precocious puberty
Ana Claudia Latronico,Vinicius Nahime Brito,Jean-Claude Carel
The Lancet Diabetes & Endocrinology. 2016;
[Pubmed] | [DOI]
7 Precocious Puberty, GnRH Stimulation Test and Monitoring GnRH Analog Therapy
P. S. N. Menon
The Indian Journal of Pediatrics. 2015; 82(11): 980
[Pubmed] | [DOI]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

   Abstract Introduction Methods Results Conclusion Article Tables
  In this article
 References

 Article Access Statistics
    Viewed3503    
    Printed28    
    Emailed2    
    PDF Downloaded701    
    Comments [Add]    
    Cited by others 7    

Recommend this journal